|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/4985 | |||
| A61P 25/28 |
| (11) | Patento numeris | 3126361 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15714951.9 |
| Europos patento paraiškos padavimo data | 2015-03-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-02-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-11-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2015/051988 |
| Data | 2015-03-18 |
| (87) | Numeris | WO 2015/150957 |
| Data | 2015-10-08 |
| (30) | Numeris | Data | Šalis |
| 201461973436 P | 2014-04-01 | US |
| (72) |
AM ENDE, Christopher William, US
HUMPHREY, John Michael, US
JOHNSON, Douglas Scott, US
KAUFFMAN, Gregory Wayne, US
PETTERSSON, Martin Youngjin, US
RANKIC, Danica Antonia, US
STEPAN, Antonia Friederike, US
VERHOEST, Patrick Robert, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS |
| CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS |